Last updated on September 2018

Pathway to Prevention Study


Brief description of study

RATIONALE

The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM.

Purpose

TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes.

The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes.

The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes.

Detailed Study Description

The Pathway to Prevention Study is conducted in two parts:

  • Screening
  • Monitoring (annual and semi-annual depending on risk)

In Screening , a simple blood test is done to screen for the presence of diabetes-related biochemical autoantibodies (GAD, IA-2A, mIAA). Islet cell autoantibodies (ICA) and ZnT8A are also measured in individuals positive for one or more biochemical autoantibodies. Participants can go to a TrialNet Clinical Center, Affiliate, or request a screening kit to have their blood drawn by a local physician or laboratory. Participants will be provided with their screening results within 4-6 weeks.

If autoantibodies are present initially and are confirmed by repeat testing, participants will be invited to have additional testing in baseline monitoring visit to determine their average risk of developing diabetes over the next 5 years. The baseline monitoring visit will include an Oral Glucose Tolerance Test (OGTT), re-testing for biochemical and islet cell autoantibodies if needed, measurement of HbA1c, and HLA (genetic) typing.

Individuals with less than 3% average risk will be asked to come for follow-up on annual basis; individuals with greater than average 32% risk will be asked to come for follow-up visits on semi-annual basis.

Participants will be monitored for possible progression towards type 1 diabetes and may be offered the opportunity to enter into a prevention study such (e.g., Oral Insulin prevention study) or an early treatment study if they are diagnosed with type 1 diabetes while participating in the Natural History Study.

Clinical Study Identifier: NCT00097292

Contact Investigators or Research Sites near you

Start Over

Stephen Gitelman, MD

University of California San Francisco
San Francisco, CA United States
  Connect »

Darrell Wilson, MD

Stanford University Medical Center
Stanford, CA United States
  Connect »

Andrea Steck, MD

Barbara Davis Center for Childhood Diabetes
Denver, CO United States
  Connect »

Kevan Herold, MD

Yale University School of Medicine
New Haven, CT United States
  Connect »

Desmond A Schatz, MD

University of Florida
Gainesville, FL United States
  Connect »

David Baidal, MD

University of Miami School of Medicine
Miami, FL United States
  Connect »

Henry Rodriguez, MD

University of South Florida Diabetes Center
Tampa, FL United States
  Connect »

Andrew Muir, MD

Emory Children's Center
Atlanta, GA United States
  Connect »

Louis Philipson, MD

University of Chicago
Chicago, IL United States
  Connect »

Linda DeMeglio, MD

Riley Hospital for Children, Indiana University
Indianapolis, IN United States
  Connect »

Antoinette Moran, MD

University of Minnesota
Minneapolis, MN United States
  Connect »

Robin S Goland, MD

Columbia University
New York, NY United States
  Connect »

Dorothy Becker, MD

Children's Hospital of Pittsburgh of UPMC
Pittsburgh, PA United States
  Connect »

William Russell, MD

Vanderbilt University
Nashville, TN United States
  Connect »

Philip Raskin, MD

University of Texas Medical Center at Dallas
Dallas, TX United States
  Connect »

Maria Redondo, MD

Baylor College of Medicine
Houston, TX United States
  Connect »

Carla Greenbaum, MD

Benaroya Research Institute
Seattle, WA United States
  Connect »

Peter C Colman, MD

Walter and Eliza Hall Institute
Parkville, Australia
  Connect »

Diane Wherrett, MD

The Hospital for Sick Children
Toronto, ON Canada
  Connect »

Jorma Toppari, MD

University of Turku
Turku, Finland
  Connect »

Wayne Moore, Md, PhD

The Children's Mercy Hospital
Kansas City, MO United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.